BonAlive Biomaterials Ltd, an emerging leader in the field of implantable medical devices for bone regeneration, has launched a castable, proprietary version and ready to use its technology of bioactive glass bone regeneration osteostimulativa BonAlive.
The launch of the putty osteostimulativa BonAlive is an important milestone in the commercialization strategy BonAlive Family Products. Current products BonAlive granules has been approved for orthopaedic use since 2006 and for the filling of bone in the treatment of chronic osteomyelitis cavities since March 2011.
"As an extension to the product line BonAlive granules, the BonAlive Putty significantly strengthen our position in the market and trauma and spinal surgeons are increasingly demanding products that are easy to use and are ready to use while offering a solid clinical outcome,” said Dr Fredrik Ollila, CEO of BonAlive Biomaterials Ltd.